查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529765

ELISpot 和 FluoroSpot 检测市场规模、份额和趋势分析报告：按产品、应用、最终用途、地区和细分市场进行预测，2024-2030 年

ELISpot And Fluorospot Assay Market Size, Share & Trends Analysis Report By Product (Assay Kits, Analyzers), By Application (Research Applications, Diagnostics Applications), By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

市场规模及趋势

2023年，全球ELISpot和FluoroSpot检测市场规模为2.9375亿美元，预计2024年至2030年复合年增长率为6.31%。这种增长是由慢性病和感染疾病的增加、药物发现活动的增加、研究和诊断的采用增加以及临床前和临床监管生物分析的扩展所推动的。 ELISpot 和 FluoroSpot 检测用于了解免疫反应，对于了解包括癌症在内的各种疾病对免疫系统的影响越来越重要。

ELISpot 和 FluoroSpot 检测用于检测和表征天然存在的肿瘤反应性 T 细胞，它们是癌症免疫疗法的合适介质。此外，这些测定已用于表位作图、肿瘤抗原鑑定以及监测疫苗诱导的 T 和 B 细胞反应。此外，肝细胞癌（HCC）和子宫颈癌的发生分别与人类乳突病毒（HPV）和B型肝炎病毒（HBV）的高风险感染密切相关。肿瘤特异性疫苗经常在动物模型和细胞株中进行测试。例如，使用 IFN-Y 和 IL-2 ELISpot 检测在小鼠和细胞株中评估人类乳突病毒(HPV)疫苗。

透过 IFN-Y ELISpot 检测对转移性子宫颈癌患者的抗原特异性T 细胞反应进行研究，有助于研究人员开发新的治疗策略。研究人员正致力于透过负载肿瘤 DNA 或肿瘤匀浆的树突状细胞诱导肿瘤特异性细胞毒性 T 淋巴细胞 (CTL) 来阻止癌症进展。另一种方法是用编码肿瘤抗原的病毒载体（例如腺病毒载体）来生产基因疫苗。肿瘤特异性CTL反应可以用ELISpot测定来确定。

IFN-Y ELISpot 测定也用于评估高剂量 IL-2 治疗对转移性黑色素瘤和肾细胞癌患者的免疫效果。 ELISpot 和 FluoroSpot 检测在癌症研究中的使用增加预计将推动需求以及癌症发生率的增加。根据美国癌症研究所的资料，每年癌症病例数预计将增加至 2,990 万，癌症相关死亡人数将达到 1,530 万人。癌症患者的快速增加预计将推动预测期内的市场成长。

这些测定为评估潜在药物对免疫系统的影响提供了强大的工具。 ELISpot 正成为多种疾病疫苗开发的重要工具，包括免疫力缺乏症候群 (AIDS)、疟疾、结核病、癌症和流感。 ELISpot 测试广泛用于评估疫苗的临床试验。根据世界卫生组织（WHO）国际临床试验註册平台（ICTRP）的资料，光是2022年，全球就进行了54,952项临床试验。临床试验和药物发现活动的增加预计将增加对 ELISpot 和 FluoroSpot 检测的需求，从而推动市场成长。

此外，多个市场参与企业正在加强努力，为各种健康状况的不同 ELISpot 和 FluoroSpot 检测开发先进的解决方案，这进一步推动了市场的成长。例如，2023 年 11 月，Revvity 宣布在印度推出 T-SPOT 测试，采用 FDA核准的ELISpot 技术，用于潜伏性结核病筛检。该测试使用标准化样本，减少了可能影响测试性能和 T 细胞计数正常化的血液因素的影响。

全球 ELISpot 和 FluoroSpot 分析市场报告细分

该报告预测了2018年至2030年全球、区域和国家层面的收益成长，并对每个子区隔的最新行业趋势进行了分析。在这项研究中，Grand View Research, Inc. 根据产品、应用、最终用途和地区对全球 ELISpot 和 FluoroSpot Assay 市场报告进行了细分。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章 ELISpot 和 FluoroSpot 侦测市场变数、趋势和范围

  • 市场体系展望
  • 市场动态
  • ELISpot 和 FluoroSpot 侦测市场分析工具

第 4 章 ELISpot 和 FluoroSpot 检测市场：按产品估算和趋势分析

  • 细分仪表板
  • 全球 ELISpot 和 FluoroSpot 检测市场的产品变化分析
  • 2018-2030 年全球 ELISpot 和 FluoroSpot 检测市场规模和趋势分析（按产品）
  • 检测套件
  • 分析仪
  • 辅助产品

第五章 ELISpot 和 FluoroSpot 检测市场：应用、估算和趋势分析

  • 细分仪表板
  • 全球ELISpot与FluoroSpot检测市场应用变化分析
  • 2018-2030 年全球 ELISpot 和 FluoroSpot 检测市场规模和趋势分析（按应用）
  • 目的
  • 诊断用途

第 6 章 ELISpot 和 FluoroSpot 检测市场：按最终用途分类的估计和趋势分析

  • 细分仪表板
  • 全球 ELISpot 和 FluoroSpot 检测市场的最终用途变化分析
  • 2018-2030 年全球 ELISpot 和 FluoroSpot 检测市场规模和趋势分析（按最终用途）
  • 医院和临床实验室
  • 学术研究所
  • 生物製药公司

第 7 章 ELISpot 和 FluoroSpot 检测市场：区域估计和趋势分析

  • 2023 年及 2030 年按地区分類的市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 公司/竞争对手分类
  • 策略规划
  • 2023 年企业市场分析
  • 公司简介/上市公司
    • Becton, Dickinson and Company
    • U-Cytech Biosciences
    • Cellular Technologies Limited
    • Mabtech AB
    • Abcam
    • Autoimmun Diagnostika GmbH
    • Lophius Biosciences GmbH
    • Bio-Connect BV
    • Oxford Immunotec
    • Bio-Techne Corporation AllCells
Product Code: GVR-4-68040-349-9

Market Size & Trends

The global ELISpot and fluorospot assay market size was valued at USD 293.75 million in 2023 and is projected to grow at a CAGR of 6.31% from 2024 to 2030. This growth can be attributed to the rising incidences of chronic and infectious diseases, increasing drug discovery activities, rising adoption in research and diagnostics, and expanding pre-clinical and clinically regulated bioanalysis. The ELISpot and Fluorospot assays are used to access immune responses, increasing their importance in understanding the effect of various diseases on the immune system, including cancer.

ELISpot and Fluorospot assay are used to detect and characterize naturally occurring tumor-reactive T-cells, which serve as suitable mediators of cancer immunotherapy. Moreover, these assays are also being used for epitope mapping, identification of tumor antigens, and monitor vaccine-induced T and B-cell responses. Moreover, the development of hepatocellular carcinoma (HCC) and cervical cancer is closely linked to high-risk infections with human papillomavirus (HPV) and hepatitis B virus (HBV), respectively. Tumor-specific vaccines are frequently tested in animal models and cell lines; for example, the HPV vaccine was assessed in mice and cell lines using the IFN-Y and IL-2 ELISPOT assay.

Detection of antigen-specific T cell responses via the IFN-Y ELISPOT assay in a patient with metastatic cervical cancer aids researchers in developing new treatment strategies. Researchers are working to halt cancer progression by inducing tumor-specific cytotoxic T lymphocytes (CTLs) through dendritic cells loaded with tumor DNA or tumor homogenate. Another approach involves generating virus-vectored genetic vaccines, such as using an Adenovirus vector encoding tumor antigens. The response of tumor-specific CTLs can be determined by the ELISPOT assay.

The IFN-Y ELISPOT assay is also used to evaluate the immunological efficacy of high-dose IL-2 treatment in patients with metastatic melanoma and renal cell carcinoma. These increasing applications of ELISpot and Fluorospot assays in cancer research are anticipated to drive their demand with increasing cancer incidences. According to National Cancer Institute data, the number of cancer cases per year is anticipated to increase to 29.9 million and cancer-related deaths to reach 15.3 million. This surge in cancer cases is anticipated to drive the market growth over the forecast period.

These assays provide a powerful tool for assessing a potential drug substance's effect on the immune system. ELISpot is emerging as a critical tool in vaccine development for various conditions, such as immunodeficiency syndrome (AIDS), malaria, tuberculosis, cancer, and flu. The ELISpot test is widely utilized in clinical studies to evaluate vaccines. According to the World Health Organization's (WHO) International Clinical Trials Registry Platform (ICTRP) data, 54,952 clinical trials were performed globally in 2022 alone. These increasing clinical trials and drug discovery activities are expected to increase the demand for ELISpot and Fluorospot assay, thereby driving market growth.

Moreover, several market players are increasing their efforts to develop advanced solutions based on ELISpot and Fluorospot assays for various health conditions, which is further driving the market growth. For instance, in November 2023, Revvity announced the launch of its FDA-approved ELISPOT technology-based T-SPOT test in India for latent TB screening. The test uses a standardized sample, which reduces the influence of blood factors that can impact the test performance and normalization for T-cell count.

Global ELISpot And Fluorospot Assay Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global ELISpot and Fluorospot assay market report based on product, application, end use, and region.

  • Product Outlook (Revenue, USD Million, 2018 - 2030)
  • Assay Kits
  • Analyzers
  • Ancillary Products
  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • Research Applications

Vaccine Development

Clinical Trials

Cancer Research

  • Diagnostics Applications

Infectious Disease

Cancer

Autoimmune Disease

Allergy and Organ Transplantations

  • End Use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospital and Clinical Labs
  • Academic and Research Institutes
  • Biopharmaceutical Company
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

  • Asia Pacific

Japan

China

India

South Korea

Australia

Thailand

  • Latin America

Brazil

Argentina

  • MEA

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Product Segment
    • 1.2.2. Application Segment
    • 1.2.3. End-use Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives
    • 1.10.1. Objective 1
    • 1.10.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. ELISpot and Fluorospot Assay Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Incidences of chronic and infectious diseases
      • 3.2.1.2. Increasing drug discovery activities
      • 3.2.1.3. Rising adoption in research and diagnostics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Complexity associated with assays
  • 3.3. ELISpot and Fluorospot Assay Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. ELISpot and Fluorospot Assay Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global ELISpot and Fluorospot Assay Market Product Movement Analysis
  • 4.3. Global ELISpot and Fluorospot Assay Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Assay Kits
    • 4.4.1. Assay kits market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Analyzers
    • 4.5.1. Analyzers market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Ancillary Products
    • 4.6.1. Ancillary Products market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. ELISpot and Fluorospot Assay Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global ELISpot and Fluorospot Assay Market Application Movement Analysis
  • 5.3. Global ELISpot and Fluorospot Assay Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
  • 5.4. Research Applications
    • 5.4.1. Research Applications market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Vaccine Development
      • 5.4.2.1. Vaccine Development market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Clinical Trials
      • 5.4.3.1. Clinical Trials market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Cancer Research
      • 5.4.4.1. Cancer Research market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Diagnostics Applications
    • 5.5.1. Diagnostics Applications market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Infectious Disease
      • 5.5.2.1. Infectious Disease market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.3. Cancer
      • 5.5.3.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.4. Autoimmune Disease
      • 5.5.4.1. Autoimmune Disease market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.5. Allergy and Organ Transplantations
      • 5.5.5.1. Allergy and Organ Transplantations market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. ELISpot and Fluorospot Assay Market: End use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global ELISpot and Fluorospot Assay Market End use Movement Analysis
  • 6.3. Global ELISpot and Fluorospot Assay Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 6.4. Hospital and Clinical Labs
    • 6.4.1. Hospital and clinical labs market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Academic and Research Institutes
    • 6.5.1. Academic and research institutes market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Biopharmaceutical Company
    • 6.6.1. Biopharmaceutical company market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. ELISpot and Fluorospot Assay Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Competitive scenario
      • 7.4.1.3. Regulatory framework
      • 7.4.1.4. Target disease prevalence
      • 7.4.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. Target disease prevalence
      • 7.4.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Mexico
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Target disease prevalence
      • 7.4.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Competitive scenario
      • 7.5.1.3. Regulatory framework
      • 7.5.1.4. Target disease prevalence
      • 7.5.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Target disease prevalence
      • 7.5.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Target disease prevalence
      • 7.5.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. Target disease prevalence
      • 7.5.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Target disease prevalence
      • 7.5.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Norway
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. Target disease prevalence
      • 7.5.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Sweden
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Target disease prevalence
      • 7.5.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Competitive scenario
      • 7.5.8.3. Regulatory framework
      • 7.5.8.4. Target disease prevalence
      • 7.5.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Competitive scenario
      • 7.6.1.3. Regulatory framework
      • 7.6.1.4. Target disease prevalence
      • 7.6.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Target disease prevalence
      • 7.6.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. India
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Target disease prevalence
      • 7.6.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Competitive scenario
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Target disease prevalence
      • 7.6.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Competitive scenario
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. Target disease prevalence
      • 7.6.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Thailand
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Competitive scenario
      • 7.6.6.3. Target disease prevalence
      • 7.6.6.4. Regulatory framework
      • 7.6.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Competitive scenario
      • 7.7.1.3. Regulatory framework
      • 7.7.1.4. Target disease prevalence
      • 7.7.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Argentina
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Target disease prevalence
      • 7.7.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Competitive scenario
      • 7.8.1.3. Regulatory framework
      • 7.8.1.4. Target disease prevalence
      • 7.8.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Competitive scenario
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Target disease prevalence
      • 7.8.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Competitive scenario
      • 7.8.3.3. Regulatory framework
      • 7.8.3.4. Target disease prevalence
      • 7.8.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.4. Kuwait
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Competitive scenario
      • 7.8.4.3. Regulatory framework
      • 7.8.4.4. Target disease prevalence
      • 7.8.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2023
  • 8.4. Company Profiles/Listing
    • 8.4.1. Becton, Dickinson and Company
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. U-Cytech Biosciences
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Cellular Technologies Limited
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Mabtech AB
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Abcam
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Autoimmun Diagnostika GmbH
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Lophius Biosciences GmbH
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Bio-Connect B.V.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Oxford Immunotec
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Bio-Techne Corporation AllCells
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 Global ELISpot and Fluorospot assay market, by region, 2018 - 2030 (USD Million)
  • Table 3 Global ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 4 Global ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 5 Global ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 6 North America ELISpot and Fluorospot assay market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 8 North America ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 9 North America ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 10 U.S. ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 11 U.S. ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 12 U.S. ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 13 Canada ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 14 Canada ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 15 Canada ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 Mexico ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 17 Mexico ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 18 Mexico ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 19 Europe ELISpot and Fluorospot assay market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 21 Europe ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 22 Europe ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 23 Germany ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 24 Germany ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 25 Germany ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 UK ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 27 UK ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 28 UK ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 29 France ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 30 France ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 31 France ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 32 Italy ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 33 Italy ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 34 Italy ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 35 Spain ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 36 Spain ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 37 Spain ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 38 Denmark ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 39 Denmark ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 40 Denmark ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 Sweden ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 42 Sweden ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 43 Sweden ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 44 Norway ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 45 Norway ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 46 Norway ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific ELISpot and Fluorospot assay market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 51 China ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 52 China ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 53 China ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 54 Japan ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 55 Japan ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 56 Japan ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 57 India ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 58 India ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 59 India ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 60 South Korea ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 61 South Korea ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 62 South Korea ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 63 Australia ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 64 Australia ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 65 Australia ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 66 Thailand ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 67 Thailand ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 68 Thailand ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 69 Latin America ELISpot and Fluorospot assay market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 71 Latin America ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 72 Latin America ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 73 Brazil ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 74 Brazil ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 75 Brazil ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 76 Argentina ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 77 Argentina ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 78 Argentina ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 79 MEA ELISpot and Fluorospot assay market, by country, 2018 - 2030 (USD Million)
  • Table 80 MEA ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 81 MEA ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 82 MEA ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 83 South Africa ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 84 South Africa ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 85 South Africa ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 89 UAE ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 90 UAE ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 91 UAE ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait ELISpot and Fluorospot assay market, by product, 2018 - 2030 (USD Million)
  • Table 93 Kuwait ELISpot and Fluorospot assay market, by application, 2018 - 2030 (USD Million)
  • Table 94 Kuwait ELISpot and Fluorospot assay market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market formulation & validation
  • Fig. 4 ELISpot and Fluorospot assay market: Market outlook
  • Fig. 5 ELISpot and Fluorospot assay market: Segment outlook
  • Fig. 6 ELISpot and Fluorospot assay market: Competitive landscape outlook
  • Fig. 7 Parent market outlook
  • Fig. 8 ELISpot and Fluorospot assay market driver impact
  • Fig. 9 ELISpot and Fluorospot assay market restraint impact
  • Fig. 10 ELISpot and Fluorospot assay market: Product outlook and key takeaways
  • Fig. 11 ELISpot and Fluorospot assay market: Product movement analysis
  • Fig. 12 Assay Kits market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Analyzers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Ancillary Products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 ELISpot and Fluorospot assay market: Application outlook and key takeaways
  • Fig. 16 ELISpot and Fluorospot assay market: Application movement analysis
  • Fig. 17 Research applications market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Vaccine development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Clinical trials market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Cancer research market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Diagnostics applications market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Infectious disease market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Autoimmune disease market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Allergy and organ transplantations market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 ELISpot and Fluorospot assay market: End-use outlook and key takeaways
  • Fig. 27 ELISpot and Fluorospot assay market: End-use movement analysis
  • Fig. 28 Hospital and clinical labs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Academic and research institutes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Biopharmaceutical company market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Global ELISpot and Fluorospot assay market: Regional outlook and key takeaways
  • Fig. 32 Global ELISpot and Fluorospot assay market: Regional movement analysis
  • Fig. 33 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)